Browse LETMD1

Summary
SymbolLETMD1
NameLETM1 domain containing 1
Aliases HCCR1; cervical cancer 1 protooncogene; 1110019O13Rik; HCRR-2; cervical cancer 1 proto-oncogene protein p40; ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion outer membrane Single-pass membrane protein
Domain PF07766 LETM1-like protein
Function

Involved in tumorigenesis and may function as a negative regulator of the p53/TP53.

> Gene Ontology
 
Biological Process -
Molecular Function GO:0043021 ribonucleoprotein complex binding
GO:0043022 ribosome binding
Cellular Component GO:0005741 mitochondrial outer membrane
GO:0005743 mitochondrial inner membrane
GO:0019867 outer membrane
GO:0031968 organelle outer membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolLETMD1
NameLETM1 domain containing 1
Aliases HCCR1; cervical cancer 1 protooncogene; 1110019O13Rik; HCRR-2; cervical cancer 1 proto-oncogene protein p40; ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LETMD1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolLETMD1
NameLETM1 domain containing 1
Aliases HCCR1; cervical cancer 1 protooncogene; 1110019O13Rik; HCRR-2; cervical cancer 1 proto-oncogene protein p40; ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LETMD1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLETMD1
NameLETM1 domain containing 1
Aliases HCCR1; cervical cancer 1 protooncogene; 1110019O13Rik; HCRR-2; cervical cancer 1 proto-oncogene protein p40; ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LETMD1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.6170.0458
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.5140.809
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.6890.668
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2150.425
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1310.938
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.320.879
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0420.911
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3260.843
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2590.887
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0780.963
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.150.954
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0640.327
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LETMD1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLETMD1
NameLETM1 domain containing 1
Aliases HCCR1; cervical cancer 1 protooncogene; 1110019O13Rik; HCRR-2; cervical cancer 1 proto-oncogene protein p40; ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LETMD1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLETMD1
NameLETM1 domain containing 1
Aliases HCCR1; cervical cancer 1 protooncogene; 1110019O13Rik; HCRR-2; cervical cancer 1 proto-oncogene protein p40; ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LETMD1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LETMD1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLETMD1
NameLETM1 domain containing 1
Aliases HCCR1; cervical cancer 1 protooncogene; 1110019O13Rik; HCRR-2; cervical cancer 1 proto-oncogene protein p40; ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LETMD1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLETMD1
NameLETM1 domain containing 1
Aliases HCCR1; cervical cancer 1 protooncogene; 1110019O13Rik; HCRR-2; cervical cancer 1 proto-oncogene protein p40; ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LETMD1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLETMD1
NameLETM1 domain containing 1
Aliases HCCR1; cervical cancer 1 protooncogene; 1110019O13Rik; HCRR-2; cervical cancer 1 proto-oncogene protein p40; ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LETMD1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLETMD1
NameLETM1 domain containing 1
Aliases HCCR1; cervical cancer 1 protooncogene; 1110019O13Rik; HCRR-2; cervical cancer 1 proto-oncogene protein p40; ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LETMD1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.